Peripheral CB1 Receptor Modulators for Metabolic Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CB1 receptor blocking drugs for treating obesity and metabolic syndrome cause neuropsychiatric side effects, leading to their withdrawal from the market and halting further therapeutic development.
Innovation Solution
Development of novel peripherally restricted cannabinoid receptor mediating compounds with a structure that includes aryl or heteroaryl groups, which selectively target CB1 receptors in peripheral tissues while minimizing brain penetration, thereby reducing neuropsychiatric side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If CB1 receptor blocking drugs are used to treat obesity and metabolic syndrome, then food intake and body weight are reduced, but neuropsychiatric side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I) that exhibit peripheral selectivity for CB1 receptors. The compounds are designed to preferentially bind to CB1 receptors in peripheral tissues (adipose, liver, muscle) while minimizing binding to CB1 receptors in the brain. This is achieved through specific substituent patterns at positions R1-R15 in the core structure, creating a drug with different pharmacological properties at different locations in the body.
Solution Approach 2:
The patent segments the CB1 receptor blocking activity into peripheral and central components by developing a series of compounds (Formulas I, II, III, IV) with progressively modified structures. The core CB1 antagonistic activity is maintained while adding peripheral-selective features through specific substituent groups, effectively separating the therapeutic peripheral effects from the harmful central effects.
2Reliability
If rimonabant is used as a CB1 receptor blocker, then metabolic syndrome is treated effectively, but the drug is withdrawn from the market due to neuropsychiatric side effects
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters (substituents at positions R1-R15, stereochemistry, functional groups) to alter the pharmacological profile of CB1 blockers. The compounds in Formulas I-IV have modified physical and chemical parameters compared to rimonabant, resulting in changed binding characteristics that favor peripheral over central CB1 receptor interaction, thereby maintaining metabolic benefits while reducing neuropsychiatric toxicity.
3Object-affected harmful factors
If peripheral CB1 receptor blocking compounds are developed, then neuropsychiatric side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent applies universality by designing a core molecular scaffold (Formula I) that serves multiple functions: it blocks CB1 receptors in peripheral tissues to treat obesity and metabolic syndrome, while the specific substituent patterns (R1-R15) provide peripheral selectivity to avoid brain penetration. The same core structure can be modified to address different metabolic parameters (food intake, body weight, insulin sensitivity, lipid profile), making it a multi-functional therapeutic platform.
Data Source
AI summary
Compounds having useful cannabinoid receptor modulating properties. The compounds may be useful in treating complications arising from metabolic, inflammatory and fibrotic disorders.